Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不就因本通告全部或任何部分內容所產生或因依賴該等內容而引致的任 何損失承擔任何責任。 承董事會命 （於中華人民共和國註冊成立的股份有限公司） 特別決議案 （股份代號：2522） 7. 審議及批准授予董事會發行新股份、出售及╱或轉讓庫存股份的一般授 權，一般授權詳情載於該通函；及 2024年年度股東會通告 – 1 – 茲通告江西一脈陽光集團股份有限公司（「本公司」）謹訂於2025年4月23日（星期 三）上午十時正假座中國北京市朝陽區民族園路2號一脈陽光醫學影像診斷中心以現場 會議結合網上虛擬會議的方式舉行2024年年度股東會（「年度股東會」），以審議並酌情 通過下列決議案（決議案詳情載於本公司日期為2025年4月1日的通函（「該通函」））： 1. 審議及批准2024年年度報告； 2. 審議及批准2024年度董事會工作報告； 3. 審議及批准2024年度監事會工作報告； 4. 審議及批准2024年度獨立 ...

此乃要件 請即處理 閣下對本通函任何方面或應採取的行動如有任何疑問，應諮詢股票經紀或其他註冊證券交易 商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓名下所有江西一脈陽光集團股份有限公司的股份，應立即將本通函連同隨 附的代表委任表格交予買主或承讓人或經手買賣或轉讓的銀行、股票經紀或其他代理，以便轉 交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本通函全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2522） (1) 2024年年度報告； (2) 2024年度董事會工作報告； (3) 2024年度監事會工作報告； (4) 2024年度獨立非執行董事述職報告； (5) 2024年度利潤分配方案； (6) 續聘2025年度核數師； (7) 發行新股份、出售及╱或轉讓庫存股份的一般授權； （8) 購回H股的一般授權； 及 (9) ...

專注影像 守護健康 江西一脈陽光集團股份有限公司 股票簡稱：一脈陽光 股票代碼：2522.HK 環境、社會及管治報告 專注影像 · 守護健康 江西一脈陽光集團股份有限公司 目 錄 | 陽光社會 · 推動社會共享及行業發展 | | --- | | 普惠醫療新佈局，優質影像資源惠及基層 | 15 | | --- | --- | | 技術驅動新變革，協同互聯推動行業發展 | 24 | | 責任擔當新實踐，醫療影像溫暖社會萬家 | 29 | 智慧陽光 · 科技助力醫療品質提升 | 智慧醫療新基建，構建全場景數智化醫療服務平臺 | 35 | | --- | --- | | 智慧醫療新實踐，人工智能輔助智慧醫療 | 41 | | 智慧醫療防火牆，隱私與數據安全 | 45 | | 智慧醫療護城河，知識產權保護 | 46 | 陽光共行 · 產業鏈協同發展 | 醫療品質新標杆，構建高標準管理體系 | 49 | | --- | --- | | 影像服務新拓展，打造多元診斷支持網絡 | 54 | | 責任採購新模式，完善供應鏈管理機制 | 58 | | 智慧服務新升級，提升就醫效率與客戶體驗 | 61 | | 陽光人本 · 打造可 ...

Business Operations and Expansion - The company has established 106 imaging centers across China, serving over hundreds of millions of patients[8]. - The company is positioned as one of the largest medical imaging data producers in China, with the fastest data accumulation and the broadest population coverage[13]. - The company is expanding its global market presence through partnerships with Huawei and iFlytek, focusing on localized cooperation[13]. - The company is transitioning from a technology service provider to a data asset operator following its inclusion in the Hong Kong Stock Connect[11]. - The company plans to expand its overseas market presence, having already established services in regions including Africa, North Asia, East Asia, Southeast Asia, Israel, and the Middle East[15]. - The company established an overseas business unit in 2024, creating a network covering regions such as Hong Kong, Macau, Southeast Asia, the Middle East, and Africa, marking the beginning of its overseas market expansion[23]. - The company aims to leverage its position as a Hong Kong-listed entity to enhance its international market reach and establish itself as a leading medical imaging service provider[15]. - The company is actively expanding its imaging center network through investments, acquisitions, and partnerships with quality social capital medical institutions[31]. - The company is focused on optimizing operational efficiency through digital management systems and enhancing its core competitiveness in the medical imaging sector[21]. - The company aims to strengthen its market position by exploring partnerships with high-quality medical institutions and leveraging industry funds for market expansion through acquisitions and mergers[23]. Financial Performance - Revenue for the year ended December 31, 2024, was RMB 760.6 million, a decrease of 18.1% compared to RMB 928.9 million in 2023[19]. - The company reported a net loss of RMB 58.9 million for 2024, a decline of 260.9% from a profit of RMB 36.6 million in 2023[19]. - EBITDA decreased by 34.7% to RMB 165.2 million in 2024 from RMB 252.9 million in 2023[19]. - The decline in revenue and profit is attributed to macroeconomic fluctuations and regulatory adjustments in the healthcare sector, leading to delays in project deliveries[20]. - Revenue from imaging center services for the year ending December 31, 2024, was approximately RMB 605.7 million, a decrease of 5.1% compared to RMB 638.1 million for the year ending December 31, 2023, primarily due to delays in the operation of several newly established imaging centers until 2025[30]. - Revenue from imaging solution services for the year ended December 31, 2024, was approximately RMB 137.6 million, a decrease of 50.6% compared to RMB 278.4 million for the year ended December 31, 2023, primarily due to delays in delivery of certain agreements to 2025[36]. - Revenue from the Yimai Cloud service for the year ended December 31, 2024, was approximately RMB 17.3 million, an increase of 38.8% from RMB 12.5 million for the year ended December 31, 2023, driven by the establishment of a "smart medical imaging ecosystem" and data asset commercialization[39]. - The company's total revenue for the year ended December 31, 2024, was approximately RMB 760.6 million, a decrease of 18.1% compared to RMB 928.9 million for the year ended December 31, 2023[51][53]. Research and Development - The company invested RMB 35.9 million in R&D over the past three years, providing services to 5,000 patients and conducting over 1.23 million remote consultations[15]. - The company launched the world's first full-modal full-process medical imaging foundation model in December 2024, marking a transition from the "1.0 era" of single disease models to the "2.0 era" of foundational models[24]. - The company is committed to exploring the integration of data and medical services, enhancing its capabilities in delivering regional smart imaging solutions through AI and big data[91]. - The company is developing AI tools for various applications, including patient diagnosis and quality control, to create a comprehensive smart imaging solution[94]. - The company is focused on promoting high-quality development of medical institutions through clinical and imaging interaction[99]. Corporate Governance - The company has established three specialized committees within the board: the Audit Committee, the Remuneration Committee, and the Nomination Committee[130]. - The company has adhered to the corporate governance code and achieved most of the recommended best practices since its listing[127]. - The board consists of nine members, including four executive directors, two non-executive directors, and three independent non-executive directors, with a term of three years[128]. - The company has appointed independent non-executive directors, ensuring that at least one possesses appropriate professional qualifications or financial management expertise, in compliance with listing rules[135]. - The company has established effective communication channels for directors to express opinions openly and confidentially when necessary[143]. Talent Development and Management - The company aims to strengthen its talent development system, focusing on cultivating professionals with medical backgrounds and business management skills to support market expansion[90]. - Employee welfare expenses increased to approximately RMB 220.6 million in 2024 from RMB 201.7 million in 2023, reflecting the company's commitment to competitive compensation and benefits[77]. - The management team has extensive experience in the healthcare industry, with the chairman having over 21 years of experience in corporate management and healthcare[104]. - The company is committed to establishing and maintaining risk management and internal control systems suitable for its business operations[200]. Market Trends and Future Strategies - The company anticipates a recovery in demand for medical imaging services by the end of 2024, driven by national healthcare infrastructure policies[20]. - Future strategies include developing regional shared imaging centers in areas with imbalanced medical resources and exploring various investment cooperation strategies[78]. - The company aims to enhance its flagship imaging centers' operational capabilities in high-demand urban areas while exploring strategic partnerships with internet hospitals[79]. - The company believes that its long-term strategic vision and solid business advancement will gradually realize the vision of "focusing on global resources, making health borderless"[40]. - The company is committed to sustainable development by reducing energy consumption through cloud film technology and ensuring proper waste management practices[96].

国家药监局综合司就《关于优化全生命周期监管支持高端医疗器械创新发展的举措(征求意见稿)》公开 征求意见。 征求意见稿提出，强化标准引领创新，进一步完善高端医疗器械标准体系。 加快发布医用外骨骼机器人、放射性核素成像设备等相关标准。 加快推进医用机器人、人工智能医疗器械、高端医学影像设备等领域的基础、通用标准和方法标准等制 修订工作，积极筹建医用机器人、人工智能医疗器械标准化技术委员会。 加强增材制造用医用材料、脑机接口柔性电极、基因工程合成生物材料等新型生物材料标准化研究。 一脉阳光(02522)：一脉阳光业务涵盖医学影像中心建设、医学影像诊断服务、影像技术培训、影像信 息化智能化服务等多个板块。一脉阳光通过建设医学影像区域共享中心和专科医联体，将三甲医院的影 像诊断能力"下沉"至县、乡。2025年1月10日，一脉阳光孵化的人工智能企业影禾医脉正式发布全球首 个全模态全流程医学影像基座大模型，引领医学影像AI行业从1.0时代进入2.0时代。 永胜医疗(01612)：公布2024年业绩，收入约8.01亿港元，同比增长 11.6%；溢利同比增加21.8%至7090 万港元，公司拥有人应占溢利6916.7万港元，同 ...

Financial Performance - The company's revenue for the year ended December 31, 2024, was RMB 760,591 thousand, a decrease of 18.1% compared to RMB 928,914 thousand in 2023[3]. - The company reported a net loss of RMB 58,858 thousand for the year, a significant decline of 260.9% from a profit of RMB 36,574 thousand in the previous year[3]. - EBITDA decreased by 34.7% to RMB 165,247 thousand from RMB 252,940 thousand in 2023[3]. - Gross profit for the same period was RMB 277,332 thousand, down 16.6% from RMB 332,597 thousand in 2023[8]. - The company's revenue for the year ended December 31, 2024, was RMB 760,591 thousand, a decrease of 18.1% compared to RMB 928,914 thousand in 2023[8]. - The company reported a net loss of RMB 58,858 thousand for 2024, compared to a profit of RMB 36,574 thousand in 2023, marking a significant decline[10]. - Administrative expenses increased to RMB 223,635 thousand in 2024, up 23.1% from RMB 181,675 thousand in 2023[8]. - The company's cash and cash equivalents rose to RMB 262,387 thousand in 2024, compared to RMB 188,835 thousand in 2023, reflecting a 39.0% increase[12]. - The total equity attributable to the owners of the company increased to RMB 1,455,648 thousand in 2024, up from RMB 1,292,627 thousand in 2023[13]. - The company's total revenue for the year ended December 31, 2024, was approximately RMB 760.6 million, a decrease of 18.1% compared to RMB 928.9 million for the year ended December 31, 2023[69]. - The decline in overall revenue was primarily due to fluctuations in the domestic macro environment and adjustments in the healthcare industry reform process, leading to delays in the delivery of certain imaging solutions and the operation of new imaging centers until 2025[70]. Business Expansion and Development - The company successfully listed on the Hong Kong Stock Exchange on June 7, 2024, raising approximately HKD 183.48 million to expand its imaging center network and seek strategic partnerships[6]. - A total of 18 new imaging center projects were developed, and 17 projects were put into operation, bringing the total to 106 operational centers across 16 provinces and municipalities in China[7]. - The company established a new overseas business department in 2024, expanding its market presence in regions including Hong Kong, Macau, Southeast Asia, the Middle East, and Africa[7]. - The company is actively exploring partnerships with leading medical institutions and industry players to enhance its competitive position in the market[7]. - The company is focusing on three growth areas: expanding deep service projects with public healthcare systems and large internet hospitals, commercializing imaging big data in clinical research and AI, and leveraging flexible imaging service modules for brand building and overseas expansion[45]. - The company is actively exploring diverse methods for expanding its imaging center business, including investment, mergers, and acquisitions, to enhance its network layout and construction[50]. - The company aims to enhance overseas market presence through a "product + service + brand" strategy, focusing on long-term growth[58]. - The company is committed to building a robust repair system in collaboration with maintenance service providers to support its medical imaging network[100]. Research and Development - The company launched the first global full-modal full-process medical imaging foundation model in December 2024, marking a transition to the "2.0 era" in medical imaging AI[7]. - The company aims to leverage AI technology and data governance to drive innovation and digital transformation in the medical imaging sector[7]. - The company has obtained 95 software copyrights and 2 medical device registration certificates related to its Yimai Cloud platform, along with 1 granted invention patent and 4 pending patent applications[56]. - The company plans to develop AI tools based on natural language processing and knowledge graphs to enhance various aspects of patient care, imaging diagnosis, quality control, and business data analysis, aiming to create a comprehensive smart imaging solution[107]. Operational Efficiency and Management - The company is focusing on optimizing its business rhythm and aligning its imaging solutions delivery with customer needs for 2025[4]. - The company is committed to enhancing its core capabilities in management, information technology, design, and professional imaging services, aiming to influence the development and efficiency of healthcare institutions[113]. - The company is focused on deepening the integration of AI and big data in medical services, aiming to enhance its regional smart imaging solutions[105]. - The company is investing in management systems to promote operational efficiency and quality control across imaging centers[106]. - The company intends to improve operational management capabilities by enhancing training systems and attracting high-skilled medical imaging and management talent[102]. Financial Position and Liabilities - The total assets of the company as of December 31, 2024, amounted to RMB 2,263,788 thousand, an increase from RMB 1,878,658 thousand in 2023[12]. - The company’s total liabilities increased to RMB 779,757 thousand in 2024, compared to RMB 543,544 thousand in 2023, indicating a rise of 43.5%[13]. - The company's financial costs for 2024 were RMB 25,272 thousand, slightly higher than RMB 24,791 thousand in 2023[8]. - The company's trade payables to third parties increased to RMB 26,485,000 in 2024 from RMB 23,482,000 in 2023, reflecting a growth of approximately 12.7%[41]. - The company reported a decrease in cash generated from operating activities to approximately RMB 12.7 million for the year ended December 31, 2024, down from RMB 201.4 million for the year ended December 31, 2023, due to delayed payments from downstream medical institutions[85]. Strategic Partnerships and Collaborations - A strategic cooperation agreement was signed with Huawei Cloud in September 2024 to jointly participate in government-level projects and develop regional medical imaging sharing centers[46]. - The company aims to build a comprehensive ecosystem around "technology + data + industry" to enhance its core imaging services and establish deep strategic partnerships with leading industry players[45]. - The company is committed to enhancing ecological collaboration with upstream and downstream companies in the medical imaging industry to enhance operational efficiency and industry position[99]. Market Trends and Regulatory Environment - Recent government policies support the healthcare sector's development, aligning the company's business model with national strategies for healthcare reform, which provides significant growth opportunities[110]. - New pricing guidelines for radiological services, including digital imaging processing and cloud storage, are expected to lower patient costs and improve hospital diagnostic capabilities, driving the development of the medical imaging industry[114].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 江西一脈陽光集團股份有限公司 董事長、執行董事兼行政總裁 陳朝陽先生 香港，2025年3月18日 於本公告日期，董事會包括執行董事陳朝陽先生、何英飛女士、馮勰先生及李飛 宇先生；非執行董事劉森林先生及郭濤先生；及獨立非執行董事吳曉輝先生、羅 毅先生及陳伊菲女士。 （股份代號：2522） 董事會會議日期 江西一脈陽光集團股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，董事 會會議將於2025年3月28日（星期五）舉行，藉以（其中包括）考慮及批准本公司及 其附屬公司截至2024年12月31日止年度之年度業績及其發佈，並考慮建議派發末 期股息（如有）。 承董事會命 （於中華人民共和國註冊成立的股份有限公司） ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 1 於本公告日期，本公司仍在審定本集團2024財政年度的年度業績。本公告所載資 料僅基於本公司管理層參照本集團2024財政年度的未經審核管理賬目及董事會現 時可獲得的資料而作出的初步評估，該等資料並未經本公司核數師或審計委員會 審核或審閱。本集團2024財政年度的實際業績可能與本公告所披露者存在差異。 根據上市規則，本集團2024財政年度的年度業績公告預期於2025年3月31日或之 前公佈。 承董事會命 （股份代號：2522） 盈利警告 本公告乃江西一脈陽光集團股份有限公司（「本公司」，連同其附屬公司，「本集 團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)條及證 券及期貨條例（香港法例第571章）第XIVA部項下的內幕消息條文而刊發。 本公司董事（「董事」）會（「董事會」）謹此通知本公司股東（「股東」）及潛在投資 ...

Investment Rating - The report maintains a "BUY" rating for Rimag Group with a new target price of HK$52.39, reflecting a 16.3% upside from the current price of HK$45.05 [4][6]. Core Insights - Rimag Group is positioned to benefit from the standardization of medical imaging data, which is crucial for advancing AI applications in healthcare. The company's initiatives in data standardization and its extensive network of medical imaging centers enhance its competitive edge [1][6]. - The introduction of the MIIA Radiological Foundation Model by Rimag's subsidiary, Medical Image Insights, aims to address the limitations of conventional medical imaging AI products by providing adaptability across multiple imaging tasks [2]. - A strategic collaboration with Xunfei Healthcare is expected to leverage Rimag's data assets and enhance its positioning in AI-enabled healthcare, focusing on joint market development and research initiatives [6]. Financial Summary - Revenue for FY22 was RMB 784 million, with a projected increase to RMB 1,050 million in FY25, reflecting a year-on-year growth of 18.0% [3][9]. - The net profit is expected to recover from a loss of RMB 15 million in FY24 to a profit of RMB 38 million in FY25, with further growth to RMB 64 million in FY26 [3][9]. - The company's price-to-sales (P/S) ratio is projected to decrease from 16.8x in FY24 to 14.3x in FY25, indicating a more favorable valuation as revenue grows [3][9]. Share Performance - Rimag's share price has shown significant volatility, with a 1-month increase of 21.8% and a 6-month increase of 147.8% [6]. - The market capitalization of Rimag Group is approximately HK$16,051.8 million, with an average turnover of HK$4.1 million over the past three months [4][6]. Strategic Initiatives - Rimag has been proactive in standardizing medical imaging examinations through its Rimag Cloud platform, which is expected to enhance the quality and availability of imaging data for AI applications [1][6]. - The company's dual role as a third-party imaging service provider and a data standardization pioneer positions it uniquely to capitalize on the growing demand for AI-driven healthcare solutions [1][6].

Summary of Conference Call on Medical Imaging Industry and Company Insights Company and Industry Overview - The conference call featured a leading company in China's third-party medical imaging services, specifically focusing on AI applications in medical imaging and the overall industry dynamics [1][2] - The company, 一脉阳光 (Yimai Yangguang), is recognized as the market leader in the third-party medical imaging sector in China [2][5] Core Insights and Arguments - The third-party medical imaging industry in China is still in its early stages, having emerged after the introduction of national standards in 2016, with significant growth potential [6][7] - The industry faces challenges due to uneven distribution of medical resources, particularly a shortage of qualified imaging doctors in grassroots healthcare institutions [5][6] - The penetration rate of third-party imaging services in China is significantly lower than in developed countries, indicating a substantial growth opportunity [7][8] - The company has developed various operational models for imaging centers, focusing on high-end health checks and providing services to smaller hospitals and clinics [9][10] - The business model involves a 2B2C approach, where hospitals purchase imaging diagnostic services from the company, enhancing operational capabilities in grassroots healthcare [10][11] Strategic Partnerships and AI Integration - A strategic partnership with Xunfei Medical was highlighted, aimed at enhancing AI capabilities in medical imaging and developing integrated service models [1][15][41] - The collaboration focuses on deploying AI in real-world scenarios, particularly in grassroots healthcare settings, to improve diagnostic efficiency and accuracy [41][42] - The company is actively working on a foundational AI model for medical imaging, which aims to enhance diagnostic capabilities across various diseases and imaging modalities [25][29][31] Data and Technology Utilization - The company possesses a vast amount of imaging data, with an average of 20,000 to 30,000 scans per day, making it one of the largest holders of imaging data in China [22][23] - Emphasis was placed on the importance of high-quality, structured imaging data for training AI models, which is currently a bottleneck in the industry [37][38] - The company is exploring the monetization of medical imaging data and aims to establish a data trading platform to enhance the value of its data assets [58][59] Market Dynamics and Future Outlook - The company anticipates a significant market shift towards AI-driven medical imaging solutions, with expectations of rapid growth in the sector [33][51] - The focus will remain on expanding its network of imaging centers, particularly in underserved areas, with plans to open 15 to 20 new centers annually [49][50] - The company aims to leverage its technological advancements and partnerships to solidify its position as a leader in the evolving medical imaging landscape [51][60] Additional Important Points - The company is committed to addressing the healthcare needs of underserved populations by providing accessible imaging services [49] - There is a strong belief in the potential for AI to transform the medical imaging field, enhancing both efficiency and diagnostic accuracy [33][51] - The call concluded with an invitation for further engagement from investors, highlighting the company's openness to discussions and collaborations [60]